{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T13:11:03Z","timestamp":1774444263808,"version":"3.50.1"},"reference-count":28,"publisher":"MDPI AG","issue":"11","license":[{"start":{"date-parts":[[2022,11,18]],"date-time":"2022-11-18T00:00:00Z","timestamp":1668729600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Viruses"],"abstract":"<jats:p>Most studies on the real-world effectiveness and safety of dolutegravir\/lamivudine (DTG\/3TC) have been conducted in Western countries, and Asian reports are lacking. We evaluated the effectiveness and safety of DTG\/3TC in Korean adult people living with HIV (PLWH). This retrospective study was conducted from July 2020 to July 2022 at a tertiary hospital in Korea. Those who were followed up for more than 12 months were included. We analyzed the baseline characteristics, effectiveness, resistant profiles, body weights, metabolic parameters, and safety of DTG\/3TC treatment in 151 PLWH, dividing them into the treatment-na\u00efve group and the switching group. The median DTG\/3TC treatment durations in the treatment-na\u00efve and switching groups were 507.5 and 525.0 days. In the treatment-na\u00efve group, the viral RNA titer was undetectable at 6 and 12 months in 95% of patients. In the switching group, virologic suppression was well-maintained. Meanwhile, the creatinine levels were slightly elevated in both groups compared to baseline. Five participants complained of mild side effects, such as indigestion, constipation, diarrhea, and fatigue. However, no patient stopped treatment during the follow-up period. Since there was no virological failure or serious complications observed in this study, DTG\/3TC may be a good treatment option for PLWH in Korea.<\/jats:p>","DOI":"10.3390\/v14112558","type":"journal-article","created":{"date-parts":[[2022,11,21]],"date-time":"2022-11-21T03:09:30Z","timestamp":1669000170000},"page":"2558","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Real-World Effectiveness, Tolerability, and Safety of Dolutegravir\/Lamivudine in Korea"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3138-6685","authenticated-orcid":false,"given":"Ki Hyun","family":"Lee","sequence":"first","affiliation":[{"name":"Department of Internal Medicine and AIDS Research Institute, Yonsei University College of Medicine, Seoul 03722, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1310-6421","authenticated-orcid":false,"given":"Jinnam","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and AIDS Research Institute, Yonsei University College of Medicine, Seoul 03722, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jung Ah","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and AIDS Research Institute, Yonsei University College of Medicine, Seoul 03722, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chang Hyup","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and AIDS Research Institute, Yonsei University College of Medicine, Seoul 03722, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jin Young","family":"Ahn","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and AIDS Research Institute, Yonsei University College of Medicine, Seoul 03722, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4025-4542","authenticated-orcid":false,"given":"Su Jin","family":"Jeong","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and AIDS Research Institute, Yonsei University College of Medicine, Seoul 03722, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9717-4327","authenticated-orcid":false,"given":"Nam Su","family":"Ku","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and AIDS Research Institute, Yonsei University College of Medicine, Seoul 03722, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2775-3315","authenticated-orcid":false,"given":"Jun Yong","family":"Choi","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and AIDS Research Institute, Yonsei University College of Medicine, Seoul 03722, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8940-7170","authenticated-orcid":false,"given":"Joon-Sup","family":"Yeom","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and AIDS Research Institute, Yonsei University College of Medicine, Seoul 03722, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0733-4156","authenticated-orcid":false,"given":"Young Goo","family":"Song","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and AIDS Research Institute, Yonsei University College of Medicine, Seoul 03722, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5033-3482","authenticated-orcid":false,"given":"Jung Ho","family":"Kim","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and AIDS Research Institute, Yonsei University College of Medicine, Seoul 03722, Republic of Korea"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,11,18]]},"reference":[{"key":"ref_1","first-page":"207","article-title":"Modern anti-hiv therapy","volume":"131","author":"Flepp","year":"2001","journal-title":"Swiss Med. Wkly."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Autenrieth, C.S., Beck, E.J., Stelzle, D., Mallouris, C., Mahy, M., and Ghys, P. (2018). Global and regional trends of people living with hiv aged 50 and over: Estimates and projections for 2000\u20132020. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0207005"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1089\/aid.2021.0041","article-title":"Real-world experience with two-drug regimens in hiv-1-infected patients beyond the indication of clinical trials: 48 weeks\u2019 results","volume":"37","author":"Moreno","year":"2021","journal-title":"AIDS Res. Hum. Retrovir."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"105893","DOI":"10.1016\/j.ijantimicag.2020.105893","article-title":"Retrospective study on the outcome of two-drug regimens based on dolutegravir plus one reverse transcriptase inhibitor in virologically-suppressed hiv-infected patients","volume":"55","author":"Galizzi","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Maggiolo, F., Gulminetti, R., Pagnucco, L., Digaetano, M., Benatti, S., Valenti, D., Callegaro, A., Ripamonti, D., and Mussini, C. (2017). Lamivudine\/dolutegravir dual therapy in hiv-infected, virologically suppressed patients. BMC Infect. Dis., 17.","DOI":"10.1186\/s12879-017-2311-2"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1093\/cid\/ciz1243","article-title":"Efficacy and safety of switching to dolutegravir\/lamivudine fixed-dose 2-drug regimen vs continuing a tenofovir alafenamide\u2013based 3-or 4-drug regimen for maintenance of virologic suppression in adults living with human immunodeficiency virus type 1: Phase 3, randomized, noninferiority tango study","volume":"71","author":"Ajana","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0140-6736(18)32462-0","article-title":"Dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate and emtricitabine in antiretroviral-naive adults with hiv-1 infection (gemini-1 and gemini-2): Week 48 results from two multicentre, double-blind, randomised, non-inferiority, phase 3 trials","volume":"393","author":"Cahn","year":"2019","journal-title":"Lancet"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"89","DOI":"10.3947\/ic.2011.43.2.89","article-title":"Clinical guidelines for the diagnosis and treatment of hiv\/aids in hiv-infected koreans","volume":"43","author":"AIDS","year":"2011","journal-title":"Infect. Chemother."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1002\/phar.2333","article-title":"A review of clinical pharmacokinetic and pharmacodynamic profiles of select antiretrovirals: Focus on differences among chinese patients","volume":"39","author":"Du","year":"2019","journal-title":"Pharmacother. J. Hum. Pharmacol. Drug Ther."},{"key":"ref_10","unstructured":"World Health Organization (2021). Guidelines: Updated Recommendations on HIV Prevention, Infant Diagnosis, Antiretroviral Initiation and Monitoring, World Health Organization."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1093\/cid\/ciu221","article-title":"Dolutegravir: A next-generation integrase inhibitor for treatment of hiv infection","volume":"59","author":"Osterholzer","year":"2014","journal-title":"Clin. Infect. Dis."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"90","DOI":"10.3389\/fphar.2015.00090","article-title":"Will drug resistance against dolutegravir in initial therapy ever occur?","volume":"6","author":"Wainberg","year":"2015","journal-title":"Front. Pharmacol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2831","DOI":"10.1097\/QAD.0000000000001279","article-title":"Intolerance of dolutegravir-containing combination antiretroviral therapy regimens in real-life clinical practice","volume":"30","author":"Oryszcyn","year":"2016","journal-title":"Aids"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"21678","DOI":"10.7448\/IAS.20.01.21678","article-title":"Dolutegravir\u2013lamivudine as initial therapy in hiv-1 infected, arv-naive patients, 48-week results of the paddle (pilot antiretroviral design with dolutegravir lamivudine) study","volume":"20","author":"Cahn","year":"2017","journal-title":"J. Int. AIDS Soc."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1097\/QAD.0b013e328323da60","article-title":"Dynamic patterns of human immunodeficiency virus type 1 integrase gene evolution in patients failing raltegravir-based salvage therapies","volume":"23","author":"Canducci","year":"2009","journal-title":"Aids"},{"key":"ref_16","unstructured":"(2021, March 01). (UNAIDS), JUNPoHaA. Unaids \u2018aids data 2020\u2019. Available online: https:\/\/www.unaids.org\/sites\/default\/files\/media_asset\/2020_aids-data-book_en.pdf."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e25484","DOI":"10.1002\/jia2.25484","article-title":"Weight gain among treatment-na\u00efve persons with hiv starting integrase inhibitors compared to non-nucleoside reverse transcriptase inhibitors or protease inhibitors in a large observational cohort in the united states and canada","volume":"23","author":"Bourgi","year":"2020","journal-title":"J. Int. AIDS Soc."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1093\/cid\/ciz407","article-title":"Greater weight gain in treatment-naive persons starting dolutegravir-based antiretroviral therapy","volume":"70","author":"Bourgi","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"ref_19","first-page":"1","article-title":"Kidney disease: Improving global outcomes (kdigo) acute kidney injury work group. Kdigo clinical practice guideline for acute kidney injury","volume":"2","author":"Kellum","year":"2012","journal-title":"Kidney Int. Suppl."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1111\/j.1365-2125.2012.04440.x","article-title":"A phase 1 study to evaluate the effect of dolutegravir on renal function via measurement of iohexol and para-aminohippurate clearance in healthy subjects","volume":"75","author":"Koteff","year":"2013","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1124\/dmd.112.048918","article-title":"In vitro investigations into the roles of drug transporters and metabolizing enzymes in the disposition and drug interactions of dolutegravir, a hiv integrase inhibitor","volume":"41","author":"Reese","year":"2013","journal-title":"Drug Metab. Dispos."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/S1473-3099(13)70257-3","article-title":"Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with hiv-1 infection (spring-2 study): 96 week results from a randomised, double-blind, non-inferiority trial","volume":"13","author":"Raffi","year":"2013","journal-title":"Lancet Infect. Dis."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1016\/S0140-6736(14)60084-2","article-title":"Once-daily dolutegravir versus darunavir plus ritonavir in antiretroviral-naive adults with hiv-1 infection (flamingo): 48 week results from the randomised open-label phase 3b study","volume":"383","author":"Clotet","year":"2014","journal-title":"Lancet"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Hua, W., Wang, S., Su, B., Wang, W., Liu, A., Li, Z., Zhang, T., Shao, Y., Ye, J., and Li, J. (2021, March 01). Evaluation of the efficacy and tolerability of dolutegravir plus lamivudine as a switch strategy in treatment-experienced hiv-infected patients. Available online: https:\/\/www.researchsquare.com\/article\/rs-80151\/v1.","DOI":"10.21203\/rs.3.rs-80151\/v1"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"477","DOI":"10.2147\/DDDT.S192124","article-title":"A nucleoside-sparing regimen of dolutegravir plus ritonavir-boosted atazanavir in hiv-1-infected patients with virological failure: The dolatav study","volume":"13","author":"Spagnuolo","year":"2019","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1007\/s13365-020-00870-z","article-title":"Lifetime antiretroviral exposure and neurocognitive impairment in hiv","volume":"26","author":"Amusan","year":"2020","journal-title":"J. Neurovirol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.ijantimicag.2019.04.009","article-title":"Pharmacokinetics of dolutegravir 100 mg once daily with rifampicin","volume":"54","author":"Wang","year":"2019","journal-title":"Int. J. Antimicrob. Agents"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1097\/QAI.0000000000000983","article-title":"The effect of dolutegravir on the pharmacokinetics of metformin in healthy subjects","volume":"72","author":"Song","year":"2016","journal-title":"J. Acquir. Immune Defic. Syndr. 1999"}],"container-title":["Viruses"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4915\/14\/11\/2558\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T01:21:37Z","timestamp":1760145697000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4915\/14\/11\/2558"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,18]]},"references-count":28,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2022,11]]}},"alternative-id":["v14112558"],"URL":"https:\/\/doi.org\/10.3390\/v14112558","relation":{},"ISSN":["1999-4915"],"issn-type":[{"value":"1999-4915","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,18]]}}}